CD8A and osteosarcoma: In osteosarcoma, systemic LPS (100 μg/kg/week in C3H/HeN mice) increases CD8+ T cell infiltration into lung metastases and reduces metastatic burden, correlating with improved PFS in human osteosarcoma—patients with high intratumoral CD8+ T cells have a median PFS of 18.6 vs. 6.6 months (220).